ESTROGEN RECEPTOR DYNAMICS AND THEIR ROLE IN NEUROPSYCHIATRIC PATHWAYS
Downloads
Objective: Growing evidence highlights that disturbances in estrogen and its signaling pathways are implicated across various psychiatric disorders. Estrogens contribute to essential brain functions, including cognition, memory, neurodevelopment, and neuroplasticity, with recent findings emphasizing their neuroprotective and anti-inflammatory properties. Method: This review synthesizes findings from cellular, preclinical, and clinical studies examining estrogen receptors in relation to psychiatric disorders, focusing on estrogen receptor activity and signaling. Results: We examine how estrogen signaling influences cognition and neuroprotection by modulating dopaminergic, serotonergic, and glutamatergic pathways and how disruptions in these mechanisms may contribute to psychiatric illnesses. Novelty: We discuss therapeutic approaches targeting estrogen signaling and propose future directions for novel treatment strategies in psychiatry, highlighting the potential of estrogens as therapeutic agents.
Our World in Data. Global Mental Health: Five Key Insights Which Emerge from the Data. Available online: https:// ourworldindata.org/global-mental-health (accessed on 29 November 2020).
Findlay, J.K.; Liew, S.H.; Simpson, E.R.; Korach, K.S. Estrogen Signaling in the Regulation of Female Reproductive Functions.
Handb. Exp. Pharmacol. 2010, 198, 29–35.
Colzato, L.S.; Hommel, B. Effects of estrogen on higher-order cognitive functions in unstressed human females may depend on individual variation in dopamine baseline levels. Front. Neurosci. 2014, 8, 65. [CrossRef] [PubMed]
Almey, A.; Milner, T.A.; Brake, W.G. Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. Horm. Behav. 2015, 74, 125–138. [CrossRef] [PubMed]
Frizell, B.; Dumas, J.A. Examining the Relationship Between Neurosteroids, Cognition, and Menopause With Neuroimaging Methods. Curr. Psychiatry Rep. 2018, 20, 96. [CrossRef]
Gasbarri, A.; Pompili, A.; D’Onofrio, A.; Cifariello, A.; Tavares, M.C.; Tomaz, C. Working memory for emotional facial expressions: Role of the estrogen in young women. Psychoneuroendocrinology 2008, 33, 964–972. [CrossRef]
Dreher, J.-C.; Schmidt, P.J.; Kohn, P.; Furman, D.; Rubinow, D.; Berman, K.F. Menstrual cycle phase modulates reward-related neural function in women. Proc. Natl. Acad. Sci. USA 2007, 104, 2465–2470. [CrossRef]
Jacobs, E.; D’Esposito, M. Estrogen shapes dopamine-dependent cognitive processes: Implications for women’s health. J. Neurosci. Off. J. Soc. Neurosci. 2011, 31, 5286–5293. [CrossRef]
Saldanha, C.J. Estrogen as a Neuroprotectant in Both Sexes: Stories From the Bird Brain. Front. Neurol. 2020, 11, 497. [CrossRef]
Azcoitia, I.; Barreto, G.E.; Garcia-Segura, L.M. Molecular mechanisms and cellular events involved in the neuroprotective actions of estradiol. Analysis of sex differences. Front. Neuroendocrinol. 2019, 55, 100787. [CrossRef]
McGregor, C.; Riordan, A.; Thornton, J. Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. Front. Neuroendocrinol. 2017, 47, 19–33. [CrossRef]
Gogos, A.; Ney, L.J.; Seymour, N.; Van Rheenen, T.E.; Felmingham, K.L. Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link? Br. J. Pharmacol. 2019, 176, 4119–4135. [CrossRef] [PubMed]
Crider, A.; Pillai, A. Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders. J. Pharmacol. Exp. Ther. 2017, 360, 48–58. [CrossRef] [PubMed]
Cho, M.; Lee, T.Y.; Kwak, Y.B.; Yoon, Y.B.; Kim, M.; Kwon, J.S. Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Aust. N. Z. J. Psychiatry 2019, 53, 742–759. [CrossRef] [PubMed]
Kulkarni, J.; Butler, S.; Riecher-Rössler, A. Estrogens and SERMS as adjunctive treatments for schizophrenia. Front. Neuroendocrinol. 2019, 53, 100743. [CrossRef]
Çakici, N.; van Beveren, N.J.M.; Judge-Hundal, G.; Koola, M.M.; Sommer, I.E.C. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis. Psychol. Med. 2019, 49, 2307–2319. [CrossRef]
Dwyer, J.B.; Aftab, A.; Radhakrishnan, R.; Widge, A.; Rodriguez, C.I.; Carpenter, L.L.; Nemeroff, C.B.; McDonald, W.M.; Kalin, N.H. Hormonal Treatments for Major Depressive Disorder: State of the Art. Am. J. Psychiatry 2020, 177, 686–705. [CrossRef]
Jeppesen, R.; Christensen, R.H.B.; Pedersen, E.M.J.; Nordentoft, M.; Hjorthøj, C.; Köhler-Forsberg, O.; Benros, M.E. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders—A comprehensive systematic review and meta-analysis. Brain Behav. Immun. 2020, 90, 364–380. [CrossRef]
Sherwin, B.B. Estrogen and Cognitive Functioning in Women: Lessons We Have Learned. Behav Neurosci. 2012, 126, 123–127. [CrossRef]
Liang, J.; Shang, Y. Estrogen and cancer. Annu. Rev. Physiol. 2013, 75, 225–240. [CrossRef]
Sayed, Y.; Taxel, P. The use of estrogen therapy in men. Curr. Opin. Pharmacol. 2003, 3, 650–654. [CrossRef]
Schulster, M.; Bernie, A.M.; Ramasamy, R. The role of estradiol in male reproductive function. Asian J. Androl. 2016, 18, 435–440. [PubMed]
Gruber, C.J.; Tschugguel, W.; Schneeberger, C.; Huber, J.C. Production and actions of estrogens. N. Engl. J. Med. 2002, 346, 340–352. [CrossRef] [PubMed]
Denley, M.C.S.; Gatford, N.J.F.; Sellers, K.J.; Srivastava, D.P. Estradiol and the Development of the Cerebral Cortex: An Unexpected Role? Front. Neurosci. 2018, 12, 245. [CrossRef] [PubMed]
Azcoitia, I.; Arevalo, M.-A.; De Nicola, A.F.; Garcia-Segura, L.M. Neuroprotective actions of estradiol revisited. Trends Endocrinol. Metab. 2011, 22, 467–473. [CrossRef] [PubMed]
Prossnitz, E.R.; Sklar, L.A.; Oprea, T.I.; Arterburn, J.B. GPR30: A novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci. 2008, 29, 116–123. [CrossRef] [PubMed]
Vrtaˇcnik, P.; Ostanek, B.; Mencej-Bedraˇc, S.; Marc, J. The many faces of estrogen signaling. Biochem. Med. 2014, 24, 329–342. [CrossRef] [PubMed]
Liu, M.-M.; Albanese, C.; Anderson, C.M.; Hilty, K.; Webb, P.; Uht, R.M.; Price, R.H., Jr.; Pestell, R.G.; Kushner, P.J. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 2002, 277, 24353–24360. [CrossRef]
Marino, M.; Galluzzo, P.; Ascenzi, P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genom. 2006, 7, 497–508. [CrossRef]
Fuentes, N.; Silveyra, P. Estrogen receptor signaling mechanisms. Adv. Protein Chem. Struct. Biol. 2019, 116, 135–170.
Hwang, W.J.; Cho, K.I.K.; Kwak, Y.B.; Lee, J.; Kim, M.; Lee, T.Y.; Kwon, J.S. Intact thalamic microstructure in asymptomatic relatives of schizophrenia patients with high genetic loading. Schizophr. Res. 2020. [CrossRef]
Prossnitz, E.R.; Arterburn, J.B. International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev. 2015, 67, 505–540. [CrossRef] [PubMed]
Montague, D.; Weickert, C.S.; Tomaskovic-Crook, E.; Rothmond, D.A.; Kleinman, J.E.; Rubinow, D.R. Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. J. Neuroendocrinol. 2008, 20, 893–903. [CrossRef] [PubMed]
Kritzer, M.F. Regional, laminar, and cellular distribution of immunoreactivity for ER alpha and ER beta in the cerebral cortex of hormonally intact, adult male and female rats. Cereb. Cortex 2002, 12, 116–128. [CrossRef] [PubMed]
Shughrue, P.J.; Lane, M.V.; Merchenthaler, I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp. Neurol. 1997, 388, 507–525. [CrossRef]
González, M.; Cabrera-Socorro, A.; Pérez-García, C.G.; Fraser, J.D.; López, F.J.; Alonso, R.; Meyer, G. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. J. Comp. Neurol. 2007, 503, 790–802. [CrossRef]
Ostlund, H.; Keller, E.; Hurd, Y.L. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann. N. Y. Acad. Sci. 2003, 1007, 54–63. [CrossRef]
Simerly, R.B.; Chang, C.; Muramatsu, M.; Swanson, L.W. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study. J. Comp. Neurol. 1990, 294, 76–95. [CrossRef]
Osterlund, M.K.; Gustafsson, J.A.; Keller, E.; Hurd, Y.L. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: Distinct distribution pattern to ERalpha mRNA. J. Clin. Endocrinol. Metab. 2000, 85, 3840–3846.
Osterlund, M.K.; Keller, E.; Hurd, Y.L. The human forebrain has discrete estrogen receptor alpha messenger RNA expression: High levels in the amygdaloid complex. Neuroscience 2000, 95, 333–342. [CrossRef]
Purves-Tyson, T.D.; Handelsman, D.J.; Double, K.L.; Owens, S.J.; Bustamante, S.; Weickert, C.S. Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci. 2012, 13, 95. [CrossRef]
Sánchez, M.G.; Bourque, M.; Morissette, M.; Di Paolo, T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010, 16, e43–e71. [CrossRef]
Yoest, K.E.; Cummings, J.A.; Becker, J.B. Oestradiol influences on dopamine release from the nucleus accumbens shell: Sex differ-ences and the role of selective oestradiol receptor subtypes. Br. J. Pharmacol. 2019, 176, 4136–4148. [CrossRef]
Wang, J.-X.; Zhuang, J.-Y.; Fu, L.; Lei, Q.; Fan, M.; Zhang, W. How ovarian hormones influence the behavioral activation and inhibition system through the dopamine pathway. PLoS ONE. 2020, 15, e0237032.
Küppers, E.; Beyer, C. Expression of estrogen receptor-alpha and beta mRNA in the developing and adult mouse striatum. Neurosci Lett. 1999, 276, 95–98. [CrossRef]
Mitra, S.W.; Hoskin, E.; Yudkovitz, J.; Pear, L.; Wilkinson, H.A.; Hayashi, S.; Pfaff, D.W.; Ogawa, S.; Rohrer, S.P.; Schaeffer, J.M.; et al. Immunolocalization of estrogen receptor beta in the mouse brain: Comparison with estrogen receptor alpha. Endocrinology 2003, 144, 2055–2067. [CrossRef] [PubMed]
Kruijver, F.P.M.; Balesar, R.; Espila, A.M.; Unmehopa, U.A.; Swaab, D.F. Estrogen-receptor-beta distribution in the human
hypothalamus: Similarities and differences with ER alpha distribution. J. Comp. Neurol. 2003, 466, 251–277. [CrossRef] [PubMed] 48. Bacqué-Cazenave, J.; Bharatiya, R.; Barrière, G.; Delbecque, J.-P.; Bouguiyoud, N.; Di Giovanni, G.; Cattaert, D.;
De Deurwaerdère, P. Serotonin in Animal Cognition and Behavior. Int. J. Mol. Sci. 2020, 21, 1649. [CrossRef] [PubMed]
Buhot, M.C. Serotonin receptors in cognitive behaviors. Curr. Opin. Neurobiol. 1997, 7, 243–254. [CrossRef]
Krolick, K.N.; Zhu, Q.; Shi, H. Effects of Estrogens on Central Nervous System Neurotransmission: Implications for Sex Differences in Mental Disorders. Prog. Mol. Biol. Transl. Sci. 2018, 160, 105–171. [PubMed]
Pecins-Thompson, M.; Brown, N.A.; Kohama, S.G.; Bethea, C.L. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J. Neurosci. Off. J. Soc. Neurosci. 1996, 16, 7021–7029. [CrossRef]
Maharjan, S.; Serova, L.I.; Sabban, E.L. Membrane-initiated estradiol signaling increases tyrosine hydroxylase promoter activity with ER alpha in PC12 cells. J. Neurochem. 2010, 112, 42–55. [CrossRef]
Becker, J.B. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci. Lett. 1990, 118, 169–171. [CrossRef]
Becker, J.B.; Ramirez, V.D. Experimental studies on the development of sex differences in the release of dopamine from striatal tissue fragments in vitro. Neuroendocrinology 1981, 32, 168–173. [CrossRef]
Becker, J.; Ramirez, V.D. Dynamics of endogenous catecholamine release from brain fragments of male and female rats.
Neuroendocrinology 1980, 31, 18–25. [CrossRef]
Hernández, M.L.; Fernández-Ruiz, J.J.; de Miguel, R.; Ramos, J.A. Time-dependent effects of ovarian steroids on tyrosine hydroxylase activity in the limbic forebrain of female rats. J. Neural Transm. Gen. Sect. 1991, 83, 77–84. [CrossRef]
Wallin-Miller, K.G.; Chesley, J.; Castrillon, J.; Wood, R.I. Sex differences and hormonal modulation of ethanol-enhanced risk taking in rats. Drug Alcohol. Depend. 2017, 174, 137–144. [CrossRef]
Hruska, R.E.; Nowak, M.W. Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum. Brain Res. 1988, 442, 349–350. [CrossRef]
Czoty, P.W.; Riddick, N.V.; Gage, H.D.; Sandridge, M.; Nader, S.H.; Garg, S.; Bounds, M.; Garg, P.K.; Nader, M.A. Effect of menstrual cycle phase on dopamine D2 receptor availability in female cynomolgus monkeys. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34, 548–554. [CrossRef]
Bazzett, T.J.; Becker, J.B. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res. 1994, 637, 163–172. [CrossRef]
Disshon, K.A.; Boja, J.W.; Dluzen, D.E. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur. J. Pharmacol. 1998, 345, 207–211. [CrossRef]
Rehavi, M.; Goldin, M.; Roz, N.; Weizman, A. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Brain Res. Mol. Brain Res. 1998, 57, 31–37. [CrossRef]
Chavez, C.; Hollaus, M.; Scarr, E.; Pavey, G.; Gogos, A.; van den Buuse, M. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: An autoradiography study. Brain Res. 2010, 1321, 51–59. [CrossRef]
Bethea, C.L.; Mirkes, S.J.; Shively, C.A.; Adams, M.R. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry 2000, 47, 562–576. [CrossRef]
Sumner, B.E.; Fink, G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res. Mol. Brain Res. 1998, 59, 205–214. [CrossRef]
Sumner, B.E.; Fink, G. Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol. Cell. Neurosci. 1993, 4, 83–92. [CrossRef]
Biegon, A.; Reches, A.; Snyder, L.; McEwen, B.S. Serotonergic and noradrenergic receptors in the rat brain: Modulation by chronic exposure to ovarian hormones. Life Sci. 1983, 32, 2015–2021. [CrossRef]
Cyr, M.; Bossé, R.; Di Paolo, T. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: Emphasis on the rat frontal cortex. Neuroscience 1998, 83, 829–836. [CrossRef]
Gundlah, C.; Pecins-Thompson, M.; Schutzer, W.E.; Bethea, C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res. Mol. Brain Res. 1999, 63, 325–339. [CrossRef]
Rivera, H.M.; Santollo, J.; Nikonova, L.V.; Eckel, L.A. Estradiol increases the anorexia associated with increased 5-HT(2C) receptor activation in ovariectomized rats. Physiol. Behav. 2012, 105, 188–194. [CrossRef]
Singh, A.; Lucki, I. Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors. Neuropharmacology 1993, 32, 331–340. [CrossRef]
Hoffman, B.J.; Hansson, S.R.; Mezey, E.; Palkovits, M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrinol. 1998, 19, 187–231. [CrossRef]
Holschneider, D.P.; Kumazawa, T.; Chen, K.; Shih, J.C. Tissue-specific effects of estrogen on monoamine oxidase A and B in the rat. Life Sci. 1998, 63, 155–160. [CrossRef]
Ortega-Corona, B.G.; Valencia-Sánchez, A.; Kubli-Garfias, C.; Anton-Tay, F.; Salazar, L.A.; Villarreal, J.E.; Ponce-Monter, H. Hypothalamic monoamine oxidase activity in ovariectomized rats after sexual behavior restoration. Arch. Med. Res. 1994, 25, 337–340.
Gazzaley, A.H.; Weiland, N.G.; McEwen, B.S.; Morrison, J.H. Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J. Neurosci. Off. J. Soc. Neurosci. 1996, 16, 6830–6838. [CrossRef]
Adams, M.M.; Fink, S.E.; Janssen, W.G.M.; Shah, R.A.; Morrison, J.H. Estrogen modulates synaptic N-methyl-D-aspartate receptor subunit distribution in the aged hippocampus. J. Comp. Neurol. 2004, 474, 419–426. [CrossRef]
Woolley, C.S.; Weiland, N.G.; McEwen, B.S.; Schwartzkroin, P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: Correlation with dendritic spine density. J. Neurosci. Off. J. Soc. Neurosci. 1997, 17, 1848–1859. [CrossRef]
Kurata, K.; Takebayashi, M.; Morinobu, S.; Yamawaki, S. beta-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms.
J. Pharmacol. Exp. Ther. 2004, 311, 237–245. [CrossRef]
Kajta, M.; Lason,´ W. Oestrogen effects on kainate-induced toxicity in primary cultures of rat cortical neurons. Acta Neurobiol. Exp. 2000, 60, 365–369.
Fischer, B.; Gleason, C.; Asthana, S. Effects of hormone therapy on cognition and mood. Fertil. Steril. 2014, 101, 898–904. [CrossRef]
Verghese, J.; Kuslansky, G.; Katz, M.J.; Sliwinski, M.; Crystal, H.A.; Buschke, H.; Lipton, R.B. Cognitive performance in surgically menopausal women on estrogen. Neurology 2000, 55, 872–874. [CrossRef]
Rissman, E.F.; Heck, A.L.; Leonard, J.E.; Shupnik, M.A.; Gustafsson, J.-A. Disruption of estrogen receptor beta gene impairs spatial learning in female mice. Proc. Natl. Acad. Sci. USA 2002, 99, 3996–4001. [CrossRef]
Rissman, E.F.; Wersinger, S.R.; Fugger, H.N.; Foster, T.C. Sex with knockout models: Behavioral studies of estrogen receptor alpha. Brain Res. 1999, 835, 80–90. [CrossRef]
Hara, Y.; Waters, E.M.; McEwen, B.S.; Morrison, J.H. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev. 2015, 95, 785–807. [CrossRef]
Khan, M.M.; Wakade, C.; de Sevilla, L.; Brann, D.W. Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia. J. Steroid Biochem. Mol. Biol. 2015, 146, 38–47. [CrossRef]
Lu, Y.; Sareddy, G.R.; Wang, J.; Wang, R.; Li, Y.; Dong, Y.; Zhang, Q.; Liu, J.; O’Connor, J.C.; Xu, J.; et al. Neuron-Derived Estrogen Regulates Synaptic Plasticity and Memory. J. Neurosci. 2019, 39, 2792–2809. [CrossRef]
Hampson, E. Estrogens, Aging, and Working Memory. Curr. Psychiatry Rep. 2018, 20, 109. [CrossRef]
Bastos, C.P.; Pereira, L.M.; Ferreira-Vieira, T.H.; Drumond, L.E.; Massensini, A.R.; Moraes, M.F.D.; Pereira, G.S. Object recognition memory deficit and depressive-like behavior caused by chronic ovariectomy can be transitorialy recovered by the acute activation of hippocampal estrogen receptors. Psychoneuroendocrinology 2015, 57, 14–25. [CrossRef]
Duff, S.J.; Hampson, E. A Beneficial Effect of Estrogen on Working Memory in Postmenopausal Women Taking Hormone Replacement Therapy. Horm. Behav. 2000, 38, 262–276. [CrossRef]
Hussain, D.; Hanafi, S.; Konishi, K.; Brake, W.G.; Bohbot, V.D. Modulation of spatial and response strategies by phase of the menstrual cycle in women tested in a virtual navigation task. Psychoneuroendocrinology 2016, 70, 108–117. [CrossRef]
Wallace, M.; Luine, V.; Arellanos, A.; Frankfurt, M. Ovariectomized rats show decreased recognition memory and spine density in the hippocampus and prefrontal cortex. Brain Res. 2006, 1126, 176–182. [CrossRef]
Tuscher, J.J.; Luine, V.; Frankfurt, M.; Frick, K.M. Estradiol-Mediated Spine Changes in the Dorsal Hippocampus and Medial Prefrontal Cortex of Ovariectomized Female Mice Depend on ERK and mTOR Activation in the Dorsal Hippocampus. J. Neurosci. Off. J. Soc. Neurosci. 2016, 36, 1483–1489. [CrossRef]
Engler-Chiurazzi, E.B.; Singh, M.; Simpkins, J.W. Reprint of: From the 90’s to now: A brief historical perspective on more than two decades of estrogen neuroprotection. Brain Res. 2016, 1645, 79–82. [CrossRef]
Hwang, W.J.; Lee, T.Y.; Shin, W.-G.; Kim, M.; Kim, J.; Lee, J.; Kwon, J.S. Global and Specific Profiles of Executive Functioning in Prodromal and Early Psychosis. Front. Psychiatry 2019, 10, 356. [CrossRef]
Bloemen, A.J.P.; Oldehinkel, A.J.; Laceulle, O.M.; Ormel, J.; Rommelse, N.N.J.; Hartman, C.A. The association between executive functioning and psychopathology: General or specific? Psychol. Med. 2018, 48, 1787–1794. [CrossRef]
Sinkeviciute, I.; Begemann, M.; Prikken, M.; Oranje, B.; Johnsen, E.; Lei, W.U.; Hugdahl, K.; Kroken, R.A.; Rau, C.; Jacobs, J.D.; et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: A meta-analysis. NPJ Schizophr. 2018, 4, 1–14. [CrossRef]
Goff, D.C.; Hill, M.; Barch, D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 2011, 99, 245–253. [CrossRef]
Keefe, R.S.E.; Meltzer, H.A.; Dgetluck, N.; Gawryl, M.; Koenig, G.; Moebius, H.J.; Lombardo, I.; Hilt, D.C. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2015, 40, 3053–3060. [CrossRef]
Pietrzak, R.H.; Olver, J.; Norman, T.; Piskulic, D.; Maruff, P.; Snyder, P.J. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol. 2009, 31, 848–859. [CrossRef]
Nuechterlein, K.H.; Green, M.F.; Kern, R.S.; Baade, L.E.; Barch, D.M.; Cohen, J.D.; Essock, S.; Fenton, W.S.; Frese, F.J., 3rd; Gold, J.M.; et al. The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am. J. Psychiatry 2008, 165, 203–213. [CrossRef]
Michalopoulou, P.G.; Lewis, S.W.; Drake, R.J.; Reichenberg, A.; Emsley, R.; Kalpakidou, A.K.; Lees, J.; Bobin, T.; Gilleen, J.K.; Pandina, G.; et al. Modafinil combined with cognitive training: Pharmacological augmentation of cognitive training in schizophre-nia. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2015, 25, 1178–1189. [CrossRef]
Harper-Harrison, G.; Shanahan, M.M. Hormone Replacement Therapy. In StatPearls; StatPearls Publishing: Treasure Is-land, FL, USA, 2020; Available online: http://www.ncbi.nlm.nih.gov/books/NBK493191/ (accessed on 29 November 2020).
Abdelhamid, R.; Luo, J.; Vandevrede, L.; Kundu, I.; Michalsen, B.; Litosh, V.A.; Schiefer, I.T.; Gherezghiher, T.; Yao, P.; Qin, Z.; et al. Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism. ACS Chem. Neurosci. 2011, 2, 256–268. [CrossRef] [PubMed]
Bourque, M.; Morissette, M.; Di Paolo, T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol. Aging 2014, 35, 2347–2356. [CrossRef] [PubMed]
Salgado, I.K.; Torrado, A.I.; Santiago, J.M.; Miranda, J.D. Tamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injury. Neural Regen. Res. 2015, 10, 385–390. [PubMed]
Kuiper, G.G.; Lemmen, J.G.; Carlsson, B.; Corton, J.C.; Safe, S.H.; van der Saag, P.T.; van der Burg, B.; Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252–4263. [CrossRef] [PubMed]
Yazgan,˘ B.; Yazgan,˘ Y.; Övey, I˙.S.; Nazıroglu,˘ M. Raloxifene and Tamoxifen Reduce PARP Activity, Cytokine and Oxidative Stress Levels in the Brain and Blood of Ovariectomized Rats. J. Mol. Neurosci. 2016, 60, 214–222. [CrossRef]
Ishihara, Y.; Itoh, K.; Ishida, A.; Yamazaki, T. Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. J. Steroid Biochem. Mol. Biol. 2015, 145, 85–93. [CrossRef]
DonCarlos, L.L.; Azcoitia, I.; Garcia-Segura, L.M. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 2009, 34 (Suppl. S1), S113–S122. [CrossRef]
Arevalo, M.A.; Santos-Galindo, M.; Lagunas, N.; Azcoitia, I.; Garcia-Segura, L.M. Selective estrogen receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 2011, 46, R1–R9. [CrossRef]
Brann, D.W.; Dhandapani, K.; Wakade, C.; Mahesh, V.B.; Khan, M.M. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications. Steroids 2007, 72, 381–405. [CrossRef]
Lu, Y.; Sareddy, G.R.; Wang, J.; Zhang, Q.; Tang, F.-L.; Pratap, U.P.; Tekmal, R.R.; Vadlamudi, R.K.; Brann, D.W. Neuron-Derived Estrogen Is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain. J. Neurosci. 2020, 40, 7355–7374. [CrossRef]
Babayan, A.H.; Kramár, E.A. Rapid Effects of Oestrogen on Synaptic Plasticity: Interactions with Actin and its Signaling Proteins. J. Neuroendocrinol. 2013, 25, 1163–1172. [CrossRef] [PubMed]
Lewis-Wambi, J.S.; Jordan, V.C. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit? Breast Cancer Res. 2009, 11, 206. [CrossRef] [PubMed]
Goodman, Y.; Bruce, A.J.; Cheng, B.; Mattson, M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 1996, 66, 1836–1844. [CrossRef] [PubMed]
Behl, C.; Widmann, M.; Trapp, T.; Holsboer, F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro.
Biochem. Biophys. Res. Commun. 1995, 216, 473–482. [CrossRef]
Rettberg, J.R.; Yao, J.; Brinton, R.D. Estrogen: A master regulator of bioenergetic systems in the brain and body. Front. Neuroen-docrinol. 2014, 35, 8–30. [CrossRef]
Villa, A.; Vegeto, E.; Poletti, A.; Maggi, A. Estrogens, Neuroinflammation, and Neurodegeneration. Endocr. Rev. 2016, 37, 372–402. [CrossRef]
Zhang, Z.; Qin, P.; Deng, Y.; Ma, Z.; Guo, H.; Guo, H.; Hou, Y.; Wang, S.; Zou, W.; Sun, Y.; et al. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation. J. Neuroinflamm. 2018, 15, 206. [CrossRef]
Hill, R.A.; van den Buuse, M. Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res. 2011, 1384, 51–60. [CrossRef]
Brown, C.M.; Mulcahey, T.A.; Filipek, N.C.; Wise, P.M. Production of proinflammatory cytokines and chemokines during neuroinflammation: Novel roles for estrogen receptors alpha and beta. Endocrinology 2010, 151, 4916–4925. [CrossRef]
Scott, E.; Zhang, Q.; Wang, R.; Vadlamudi, R.; Brann, D. Estrogen neuroprotection and the critical period hypothesis. Front. Neuroendocrinol. 2012, 33, 85–104. [CrossRef]
Jablensky, A.; McGrath, J.; Herrman, H.; Castle, D.; Gureje, O.; Evans, M.; Carr, V.; Morgan, V.; Korten, A.; Harvey, C. Psychotic disorders in urban areas: An overview of the Study on Low Prevalence Disorders. Aust. N. Z. J. Psychiatry 2000, 34, 221–236. [CrossRef] [PubMed]
Huber, T.J.; Rollnik, J.; Wilhelms, J.; von zur Mühlen, A.; Emrich, H.M.; Schneider, U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001, 26, 27–35. [CrossRef]
Biegon, A.; McEwen, B.S. Modulation by estradiol of serotonin receptors in brain. J. Neurosci. 1982, 2, 199–205. [CrossRef] [PubMed]
Goldstein, J.M.; Link, B.G. Gender and the expression of schizophrenia. J. Psychiatr. Res. 1988, 22, 141–155. [CrossRef]
Riecher-Rössler, A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 2017, 4, 63–72. [CrossRef]
Mahé, V.; Dumaine, A. Oestrogen withdrawal associated psychoses. Acta Psychiatr. Scand. 2001, 104, 323–331. [CrossRef]
Riecher-Rössler, A.; Häfner, H.; Stumbaum, M.; Maurer, K.; Schmidt, R. Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 1994, 20, 203–214. [CrossRef]
Gurvich, C.; Gavrilidis, E.; Worsley, R.; Hudaib, A.; Thomas, N.; Kulkarni, J. Menstrual cycle irregularity and menopause status influence cognition in women with schizophrenia. Psychoneuroendocrinology 2018, 96, 173–178. [CrossRef]
Chang, S.S.; Renshaw, D.C. Psychosis and pregnancy. Compr. Ther. 1986, 12, 36–41.
Wei, S.-M.; Berman, K.F. Ovarian hormones, genes, and the brain: The case of estradiol and the brain-derived neurotrophic factor (BDNF) gene. Neuropsychopharmacology 2019, 44, 223–224. [CrossRef]
Damme, K.S.F.; Ristanovic, I.; Vargas, T.; Mittal, V.A. Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis. Psychoneuroendocrinology 2020, 117, 104672. [CrossRef] [PubMed]
Kulkarni, J.; Gavrilidis, E.; Worsley, R.; Hayes, E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs 2012, 26, 549–557. [CrossRef] [PubMed]
Hoff, A.L.; Kremen, W.S.; Wieneke, M.H.; Lauriello, J.; Blankfeld, H.M.; Faustman, W.O.; Csernansky, J.G.; Nordahl, T.E. Association of Estrogen Levels With Neuropsychological Performance in Women With Schizophrenia. Am. J. Psychiatry 2001, 158, 1134–1139. [CrossRef] [PubMed]
Mendrek, A.; Lakis, N.; Jiménez, J. Associations of sex steroid hormones with cerebral activations during mental rotation in men and women with schizophrenia. Psychoneuroendocrinology 2011, 36, 1422–1426. [CrossRef]
Célia Moreira Borella, V.; Seeman, M.V.; Carneiro Cordeiro, R.; Vieira dos Santos, J.; Romário Matos de Souza, M.; Nunes de Sousa Fernandes, E.; Santos Monte, A.; Maria Mendes Vasconcelos, S.; Quinn, J.P.; de Lucena, D.F.; et al. Gender and estrous cycle influences on behavioral and neurochemical alterations in adult rats neonatally administered ketamine. Dev. Neurobiol. 2016, 76, 519–532. [CrossRef]
Gogos, A.; Kwek, P.; van den Buuse, M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology 2012, 219, 213–224. [CrossRef]
Gogos, A.; van den Buuse, M. Comparing the effects of 17 -oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats. Schizophr. Res. 2015, 168, 634–639. [CrossRef]
Sbisa, A.; Kusljic, S.; Zethoven, D.; van den Buuse, M.; Gogos, A. The effect of 17 -estradiol on maternal immune activation-induced changes in prepulse inhibition and dopamine receptor and transporter binding in female rats. Schizophr. Res. 2020, 223, 249–257. [CrossRef]
Riecher-Rössler, A.; Kulkarni, J. Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. In Biological Basis of Sex Differences in Psychopharmacology; Current Topics in Behavioral Neurosciences; Neill, J.C., Kulkarni, J., Eds.; Springer: Berlin/Heidelberg, Germany, 2011; pp. 155–171. [CrossRef]
Da Silva, T.L.; Ravindran, A.V. Contribution of sex hormones to gender differences in schizophrenia: A review. Asian J. Psychiatry 2015, 18, 2–14. [CrossRef]
Perlman, W.R.; Tomaskovic-Crook, E.; Montague, D.M.; Webster, M.J.; Rubinow, D.R.; Kleinman, J.E.; Weickert, C.S. Alteration in estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol. Psychiatry 2005, 58, 812–824. [CrossRef]
Weickert, C.S.; Miranda-Angulo, A.L.; Wong, J.; Perlman, W.R.; Ward, S.E.; Radhakrishna, V.; Straub, R.E.; Weinberger, D.R.; Kleinman, J.E. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 2008, 17, 2293–2309. [CrossRef] [PubMed]
Kinon, B.J.; Gilmore, J.A.; Liu, H.; Halbreich, U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28 (Suppl. S2), 55–68. [CrossRef]
Canuso, C.M.; Goldstein, J.M.; Wojcik, J.; Dawson, R.; Brandman, D.; Klibanski, A.; Schildkraut, J.J.; Green, A.I. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002, 111, 11–20. [CrossRef]
Aston, J.; Rechsteiner, E.; Bull, N.; Borgwardt, S.; Gschwandtner, U.; Riecher-Rössler, A. Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 1342–1344. [CrossRef] [PubMed]
Ittig, S.; Studerus, E.; Heitz, U.; Menghini-Müller, S.; Beck, K.; Egloff, L.; Leanza, L.; Andreou, C.; Riecher-Rössler, A. Sex differ-ences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophr. Res. 2017, 189, 111–116. [CrossRef] [PubMed]
Petrikis, P.; Tigas, S.; Tzallas, A.T.; Archimandriti, D.T.; Skapinakis, P.; Mavreas, V. Prolactin levels in drug-naïve patients with schizophrenia and other psychotic disorders. Int. J. Psychiatry Clin. Pract. 2016, 20, 165–169. [CrossRef] [PubMed]
Riecher-Rössler, A.; Rybakowski, J.K.; Pflueger, M.O.; Beyrau, R.; Kahn, R.S.; Malik, P.; Fleischhacker, W.W.; EUFEST Study Group. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med. 2013, 43, 2571–2582.
Du, X.; Hill, R.A. Hypothalamic-pituitary-gonadal axis dysfunction: An innate pathophysiology of schizophrenia? Gen. Comp. Endocrinol. 2019, 275, 38–43. [CrossRef]
Bergemann, N.; Parzer, P.; Jaggy, S.; Auler, B.; Mundt, C.; Maier-Braunleder, S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: Results of a double-blind, placebo-controlled trial. Schizophr. Bull. 2008, 34, 1172–1181. [CrossRef]
Kulkarni, J.; Gavrilidis, E.; Wang, W.; Worsley, R.; Fitzgerald, P.B.; Gurvich, C.; Van Rheenen, T.; Berk, M.; Burger, H. Estradiol for treatment-resistant schizophrenia: A large-scale randomized-controlled trial in women of child-bearing age. Mol. Psychiatry 2015, 20, 695–702. [CrossRef]
Khodaie-Ardakani, M.-R.; Khosravi, M.; Zarinfard, R.; Nejati, S.; Mohsenian, A.; Tabrizi, M.; Akhondzadeh, S. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Med. Iran. 2015, 53, 337–345. [PubMed]
Kulkarni, J.; Gavrilidis, E.; Gwini, S.M.; Worsley, R.; Grigg, J.; Warren, A.; Gurvich, C.; Gilbert, H.; Berk, M.; Davis, S.R. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial. JAMA Psychiatry 2016, 73, 947–954. [CrossRef] [PubMed]
Weickert, T.W.; Weinberg, D.; Lenroot, R.; Catts, S.V.; Wells, R.; Vercammen, A.; O’Donnell, M.; Galletly, C.; Liu, D.; Balzan, R.; et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol. Psychiatry 2015, 20, 685–694. [CrossRef] [PubMed]
Huerta-Ramos, E.; Labad, J.; Cobo, J.; Núñez, C.; Creus, M.; García-Parés, G.; Cuadras, D.; Franco, J.; Miquel, E.; Reyes, J.C.; et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial. Eur. Arch. Psychiatry Clin. Neurosci. 2020, 270, 729–737. [CrossRef]
Shivakumar, V.; Venkatasubramanian, G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia.
Indian J. Psychiatry 2012, 54, 394. [CrossRef]
Orhan, F.Ö.; Kuruta¸s, E.B.; Doganer,˘ A.; Türker, E.; Özcü, S.S¸.T.; Güngör, M.; Çakmak, S. Serum levels of GPER-1 in euthymic bipolar patients. Neuropsychiatr. Dis Treat. 2018, 14, 855–862. [CrossRef]
Middle, F.; Jones, I.; Robertson, E.; Morey, J.; Lendon, C.; Craddock, N. Variation in the coding sequence and flanking splice junctions of the estrogen receptor alpha (ERalpha) gene does not play an important role in genetic susceptibility to bipolar disorder or bipolar affective puerperal psychosis. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 2003, 118B, 72–75. [CrossRef]
Kealey, C.; Reynolds, A.; Mynett-Johnson, L.; Claffey, E.; McKeon, P. No evidence to support an association between the oestrogen receptor beta gene and bipolar disorder. Psychiatr. Genet. 2001, 11, 223–226. [CrossRef]
Dias, R.S.; Lafer, B.; Russo, C.; Del Debbio, A.; Nierenberg, A.A.; Sachs, G.S.; Joffe, H. Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: Findings from STEP-BD. Am. J. Psychiatry 2011, 168, 386–394. [CrossRef]
Perich, T.A.; Roberts, G.; Frankland, A.; Sinbandhit, C.; Meade, T.; Austin, M.-P.; Mitchell, P.B. Clinical characteristics of women with reproductive cycle-associated bipolar disorder symptoms. Aust. N. Z. J. Psychiatry 2017, 51, 161–167. [CrossRef]
Fallah, E.; Arman, S.; Najafi, M.; Shayegh, B. Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents. Iran. J. Child Neurol. 2016, 10, 16–25. [PubMed]
Palacios, J.; Yildiz, A.; Young, A.H.; Taylor, M.J. Tamoxifen for bipolar disorder: Systematic review and meta-analysis.
J. Psychopharmacol. Oxf. Engl. 2019, 33, 177–184. [CrossRef] [PubMed]
Valvassori, S.S.; Dal-Pont, G.C.; Resende, W.R.; Varela, R.B.; Peterle, B.R.; Gava, F.F.; Mina, F.G.; Cararo, J.H.; Carvalho, A.F.; Quevedo, J. Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain. Int. J. Neuropsychopharmacol. 2017, 20, 877–885. [CrossRef] [PubMed]
Bäckström, T.; Sanders, D.; Leask, R.; Davidson, D.; Warner, P.; Bancroft, J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom. Med. 1983, 45, 503–507. [CrossRef] [PubMed]
Findikli, E.; Kurutas, E.B.; Camkurt, M.A.; Karaaslan, M.F.; Izci, F.; Fındıklı, H.A.; Karda¸s, S.; Dag, B.; Altun, H. Increased Serum G Protein-coupled Estrogen Receptor 1 Levels and Its Diagnostic Value in Drug Naïve Patients with Major Depressive Disorder.
Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol. 2017, 15, 337–342. [CrossRef] [PubMed]
Skovlund, C.W.; Mørch, L.S.; Kessing, L.V.; Lange, T.; Lidegaard, Ø. Association of Hormonal Contraception with Suicide Attempts and Suicides. Am. J. Psychiatry 2018, 175, 336–342. [CrossRef] [PubMed]
Skovlund, C.W.; Mørch, L.S.; Kessing, L.V.; Lidegaard, Ø. Association of Hormonal Contraception with Depression. JAMA Psychiatry 2016, 73, 1154–1162. [CrossRef]
Frye, C.A.; Walf, A.A. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm. Behav. 2002, 41, 306–315. [CrossRef]
Rachman, I.M.; Unnerstall, J.R.; Pfaff, D.W.; Cohen, R.S. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc. Natl. Acad. Sci. USA 1998, 95, 13941–13946. [CrossRef]
Hodis, H.N.; Mack, W.J.; Henderson, V.W.; Shoupe, D.; Budoff, M.J.; Hwang-Levine, J.; Li, Y.; Feng, M.; Dustin, L.; Kono, N.; et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N. Engl. J. Med. 2016, 374, 1221–1231. [CrossRef]
Loomes, R.; Hull, L.; Mandy, W.P.L. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. J. Am. Acad. Child Adolesc. Psychiatry 2017, 56, 466–474. [PubMed]
Baron-Cohen, S.; Auyeung, B.; Nørgaard-Pedersen, B.; Hougaard, D.M.; Abdallah, M.W.; Melgaard, L.; Cohen, A.S.; Chakrabarti, B.; Ruta, L.; Lombardo, M.V. Elevated fetal steroidogenic activity in autism. Mol. Psychiatry 2015, 20, 369–376. [CrossRef] [PubMed]
Crespi, B.J. Oxytocin, testosterone, and human social cognition. Biol. Rev. Camb. Philos. Soc. 2016, 91, 390–408. [CrossRef] [PubMed]
Baron-Cohen, S. The extreme male brain theory of autism. Trends Cogn. Sci. 2002, 6, 248–254. [CrossRef]
Srivastava, D.P.; Woolfrey, K.M.; Liu, F.; Brandon, N.J.; Penzes, P. Estrogen receptor ß activity modulates synaptic signaling and structure. J. Neurosci. Off. J. Soc. Neurosci. 2010, 30, 13454–13460. [CrossRef]
Crider, A.; Thakkar, R.; Ahmed, A.O.; Pillai, A. Dysregulation of estrogen receptor beta (ER ), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects. Mol. Autism 2014, 5, 46. [CrossRef]
Chakrabarti, B.; Dudbridge, F.; Kent, L.; Wheelwright, S.; Hill-Cawthorne, G.; Allison, C.; Banerjee-Basu, S.; Baron-Cohen, S. Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and As-perger syndrome. Autism Res. Off. J. Int. Soc. Autism Res. 2009, 2, 157–177. [CrossRef]
Rucklidge, J.J. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr. Clin. N. Am. 2010, 33, 357–373. [CrossRef]
Quinn, P.O. Treating adolescent girls and women with ADHD: Gender-specific issues. J. Clin. Psychol. 2005, 61, 579–587. [CrossRef]
Sahin, N.; Altun, H.; Kuruta¸s, E.B.; Fındıklı, E. Evaluation of estrogen and G protein-coupled estrogen receptor 1 (GPER) levels in drug-naïve patients with attention deficit hyperactivity disorder (ADHD). Bosn. J. Basic Med. Sci. 2018, 18, 126–131. [CrossRef]
Schug, T.T.; Blawas, A.M.; Gray, K.; Heindel, J.J.; Lawler, C.P. Elucidating the links between endocrine disruptors and neurodevel-opment. Endocrinology 2015, 156, 1941–1951. [CrossRef] [PubMed]
Matsuda, S.; Matsuzawa, D.; Ishii, D.; Tomizawa, H.; Sutoh, C.; Nakazawa, K.; Amano, K.; Sajiki, J.; Shimizu, E. Effects of perinatal exposure to low dose of bisphenol A on anxiety like behavior and dopamine metabolites in brain. Prog. Neuropsychopharmacol.
Biol. Psychiatry 2012, 39, 273–279. [CrossRef] [PubMed]
Wilens, T.E. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 2008, 28 (Suppl. S2), S46–S53. [CrossRef] [PubMed]
Casas, M.; Forns, J.; Martínez, D.; Avella-García, C.; Valvi, D.; Ballesteros-Gómez, A.; Luque, N.; Rubio, S.; Julvez, J.; Sunyer, J.; et al. Exposure to bisphenol A during pregnancy and child neuropsychological development in the INMA-Sabadell cohort. Environ. Res. 2015, 142, 671–679. [CrossRef] [PubMed]
Rochester, J.R.; Bolden, A.L.; Kwiatkowski, C.F. Prenatal exposure to bisphenol A and hyperactivity in children: A systematic review and meta-analysis. Environ. Int. 2018, 114, 343–356. [CrossRef] [PubMed]
McLean, C.P.; Asnaani, A.; Litz, B.T.; Hofmann, S.G. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. J. Psychiatr. Res. 2011, 45, 1027–1035. [CrossRef] [PubMed]
Hayward, C.; Sanborn, K. Puberty and the emergence of gender differences in psychopathology. J. Adolesc. Health 2002, 30 (Suppl. S1), 49–58. [CrossRef]
Fındıklı, E.; Camkurt, M.A.; Karaaslan, M.F.; Kurutas, E.B.; Altun, H.; Izci,˙ F.; Fındıklı, H.A.; Kardas, S. Serum levels of G protein-coupled estrogen receptor 1 (GPER1) in drug-naive patients with generalized anxiety disorder. Psychiatry Res. 2016, 244, 312–316. [CrossRef]
Zheng, Y.; Wu, M.; Gao, T.; Meng, L.; Ding, X.; Meng, Y.; Jiao, Y.; Luo, P.; He, Z.; Sun, T.; et al. GPER-Deficient Rats Exhibit Lower Serum Corticosterone Level and Increased Anxiety-Like Behavior. Neural Plast. 2020, 2020, 8866187. [CrossRef]
Solomon, M.B.; Herman, J.P. Sex differences in psychopathology: Of gonads, adrenals and mental illness. Physiol. Behav. 2009, 97, 250–258. [CrossRef]
Dombret, C.; Naulé, L.; Trouillet, A.-C.; Parmentier, C.; Hardin-Pouzet, H.; Mhaouty-Kodja, S. Effects of neural estrogen receptor beta deletion on social and mood-related behaviors and underlying mechanisms in male mice. Sci. Rep. 2020, 10, 6242. [CrossRef] [PubMed]
Miller, C.K.; Krentzel, A.A.; Patisaul, H.B.; Meitzen, J. Metabotropic glutamate receptor subtype 5 (mGlu5) is necessary for estradiol mitigation of light-induced anxiety behavior in female rats. Physiol. Behav. 2020, 214, 112770. [CrossRef] [PubMed]
Kessler, R.C.; Aguilar-Gaxiola, S.; Alonso, J.; Benjet, C.; Bromet, E.J.; Cardoso, G.; Degenhardt, L.; de Girolamo, G.; Dinolova, R.V.; Ferry, F.; et al. Trauma and PTSD in the WHO World Mental Health Surveys. Eur. J. Psychotraumatol. 2017, 8 (Suppl. S5), 1353383. [CrossRef] [PubMed]
Wade, D.; Varker, T.; Kartal, D.; Hetrick, S.; O’Donnell, M.; Forbes, D. Gender difference in outcomes following trauma-focused interventions for posttraumatic stress disorder: Systematic review and meta-analysis. Psychol. Trauma Theory Res. Pract. Policy 2016, 8, 356–364. [CrossRef]
Ney, L.J.; Matthews, A.; Bruno, R.; Felmingham, K.L. Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. Neurosci. Biobehav. Rev. 2018, 94, 302–320. [CrossRef]
Glover, E.M.; Jovanovic, T.; Norrholm, S.D. Estrogen and Extinction of Fear Memories: Implications for Posttraumatic Stress Disorder Treatment. Biol. Psychiatry 2015, 78, 178–185. [CrossRef]
Nillni, Y.I.; Pineles, S.L.; Patton, S.C.; Rouse, M.H.; Sawyer, A.T.; Rasmusson, A.M. Menstrual cycle effects on psychological symptoms in women with PTSD. J. Trauma. Stress 2015, 28, 1–7. [CrossRef]
Lind, M.J.; Marraccini, M.E.; Sheerin, C.M.; Bountress, K.; Bacanu, S.-A.; Amstadter, A.B.; Nugent, N.R. Association of Post-traumatic Stress Disorder With rs2267735 in the ADCYAP1R1 Gene: A Meta-Analysis. J. Trauma. Stress 2017, 30, 389–398. [CrossRef]
Maddox, S.A.; Kilaru, V.; Shin, J.; Jovanovic, T.; Almli, L.M.; Dias, B.G.; Norrholm, S.D.; Fani, N.; Michopoulos, V.; Ding, Z.; et al. Estrogen-dependent association of HDAC4 with fear in female mice and women with PTSD. Mol. Psychiatry 2018, 23, 658–665. [CrossRef]
Feng, Y.; Su, M.; Si, Y.J.; Guo, Q.W.; Lin, J.; Cao, T.; Zhang, X.; Fan, M.; Fang, D.Z. Longitudinal interplays of estrogen receptor alpha gene rs9340799 with social-environmental factors on post-traumatic stress disorder in Chinese Han adolescents after Wenchuan earthquake. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 2018, 177, 337–345. [CrossRef]
Feng, Y.; Lin, J.; Su, M.; Zhang, X.; Fang, D.Z. Interplays of estrogen receptor alpha gene rs2234693 with post-traumatic stress disorder influence serum glucose and lipids profiles in Chinese adolescents. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas 2019, 61, 36–43. [CrossRef] [PubMed]
Sartin-Tarm, A.; Ross, M.C.; Privatsky, A.A.; Cisler, J.M. Estradiol Modulates Neural and Behavioral Arousal in Women with Posttraumatic Stress Disorder During a Fear Learning and Extinction Task. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2020, 5, 1114–1122. [PubMed]
Udo, T.; Grilo, C.M. Prevalence and Correlates of DSM-5-Defined Eating Disorders in a Nationally Representative Sample of U.S. Adults. Biol. Psychiatry 2018, 84, 345–354. [CrossRef] [PubMed]
Culbert, K.M.; Sinclair, E.B.; Hildebrandt, B.A.; Klump, K.L.; Sisk, C.L. Perinatal testosterone contributes to mid-to-post pubertal sex differences in risk for binge eating in male and female rats. J. Abnorm. Psychol. 2018, 127, 239–250. [CrossRef]
Mikhail, M.E.; Culbert, K.M.; Sisk, C.L.; Klump, K.L. Gonadal hormone contributions to individual differences in eating disorder risk. Curr. Opin. Psychiatry 2019, 32, 484–490. [CrossRef]
Asarian, L.; Geary, N. Sex differences in the physiology of eating. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R1215–R1267. [CrossRef]
Klump, K.L.; Fowler, N.; Mayhall, L.; Sisk, C.L.; Culbert, K.M.; Burt, S.A. Estrogen moderates genetic influences on binge eating during puberty: Disruption of normative processes? J. Abnorm. Psychol. 2018, 127, 458–470. [CrossRef]
Lutter, M.; Khan, M.Z.; Satio, K.; Davis, K.C.; Kidder, I.J.; McDaniel, L.; Darbro, B.W.; Pieper, A.A.; Cui, H. The Eating-Disorder Associated HDAC4A778T Mutation Alters Feeding Behaviors in Female Mice. Biol. Psychiatry 2017, 81, 770–777. [CrossRef]
McElroy, S.L.; Guerdjikova, A.I.; Mori, N.; Keck, P.E. Psychopharmacologic treatment of eating disorders: Emerging findings.
Curr. Psychiatry Rep. 2015, 17, 35. [CrossRef]
Brady, K.T.; Randall, C.L. Gender differences in substance use disorders. Psychiatr. Clin. N. Am. 1999, 22, 241–252. [CrossRef]
Agabio, R.; Campesi, I.; Pisanu, C.; Gessa, G.L.; Franconi, F. Sex differences in substance use disorders: Focus on side effects. Addict. Biol. 2016, 21, 1030–1042. [CrossRef] [PubMed]
Szabo, G. Women and alcoholic liver disease-warning of a silent danger. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 253–254. [CrossRef] [PubMed]
Martel, M.M.; Eisenlohr-Moul, T.; Roberts, B. Interactive effects of ovarian steroid hormones on alcohol use and binge drinking across the menstrual cycle. J. Abnorm. Psychol. 2017, 126, 1104–1113. [CrossRef] [PubMed]
Satta, R.; Hilderbrand, E.R.; Lasek, A.W. Ovarian Hormones Contribute to High Levels of Binge-Like Drinking by Female Mice. Alcohol. Clin. Exp. Res. 2018, 42, 286–294. [CrossRef]
Vandegrift, B.J.; Hilderbrand, E.R.; Satta, R.; Tai, R.; He, D.; You, C.; Chen, H.; Xu, P.; Coles, C.; Brodie, M.S.; et al. Estrogen Receptor Regulates Ethanol Excitation of Ventral Tegmental Area Neurons and Binge Drinking in Female Mice. J. Neurosci. Off. J. Soc. Neurosci. 2020, 40, 5196–5207. [CrossRef]
Copyright (c) 2026 Rusul Abdulridha Issa, Sama A. F. Al Rubaie
This work is licensed under a Creative Commons Attribution 4.0 International License.
